C6 pyridinium ceramide influences alternative pre-mRNA splicing by inhibiting protein phosphatase-1

Chiranthani Sumanasekera, Olga Kelemen, Monique Beullens, Brandon E. Aubol, Joseph A. Adams, Manjula Sunkara, Andrew Morris, Mathieu Bollen, Athena Andreadis, Stefan Stamm

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Alternative pre-mRNA processing is a central element of eukaryotic gene regulation. The cell frequently alters the use of alternative exons in response to physiological stimuli. Ceramides are lipid-signaling molecules composed of sphingosine and a fatty acid. Previously, water-insoluble ceramides were shown to change alternative splicing and decrease SR-protein phosphorylation by activating protein phosphatase-1 (PP1). To gain further mechanistical insight into ceramide-mediated alternative splicing, we analyzed the effect of C6 pyridinium ceramide (PyrCer) on alternative splice site selection. PyrCer is a water-soluble ceramide analog that is under investigation as a cancer drug. We found that PyrCer binds to the PP1 catalytic subunit and inhibits the dephosphorylation of several splicing regulatory proteins containing the evolutionarily conserved RVxF PP1-binding motif (including PSF/SFPQ, Tra2-beta1 and SF2/ASF). In contrast to natural ceramides, PyrCer promotes phosphorylation of splicing factors. Exons that are regulated by PyrCer have in common suboptimal splice sites, are unusually short and share two 4-nt motifs, GAAR and CAAG. They are dependent on PSF/SFPQ, whose phosphorylation is regulated by PyrCer. Our results indicate that lipids can influence pre-mRNA processing by regulating the phosphorylation status of specific regulatory factors, which is mediated by protein phosphatase activity.

Original languageEnglish
Pages (from-to)4025-4039
Number of pages15
JournalNucleic Acids Research
Volume40
Issue number9
DOIs
StatePublished - May 2012

Bibliographical note

Funding Information:
European Alternative Splicing Network of Excellence (EURASNET) (LSHG-CT-2005-518238) and National Institutes of Health (R21HD056195, 2P20 RR020171, P20RR021954 and RO1GM083187, GM50388, GM67969) as well as an ARRA supplement to J.A.A. Funding for open access charge: National Institutes of Health (RO1GM083187).

Funding

European Alternative Splicing Network of Excellence (EURASNET) (LSHG-CT-2005-518238) and National Institutes of Health (R21HD056195, 2P20 RR020171, P20RR021954 and RO1GM083187, GM50388, GM67969) as well as an ARRA supplement to J.A.A. Funding for open access charge: National Institutes of Health (RO1GM083187).

FundersFunder number
EURASNETLSHG-CT-2005-518238
National Institutes of Health (NIH)R21HD056195, RO1GM083187, GM50388, P20RR021954, GM67969, 2P20 RR020171
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical SciencesT32GM007752

    ASJC Scopus subject areas

    • Genetics

    Fingerprint

    Dive into the research topics of 'C6 pyridinium ceramide influences alternative pre-mRNA splicing by inhibiting protein phosphatase-1'. Together they form a unique fingerprint.

    Cite this